Sort   by:  
 Page size 
TranscriptomicsA 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
To determine the differential expression of KRAS-variant HNSCC (head and neck squamous cell carcinoma) cell lines. Total RNA collected from a panel of HNSCC cell lines.
ORGANISM(S): Homo sapiens 
2014-10-02 | E-GEOD-36110 | biostudies-arrayexpress
UnknownA let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Not available
S-EPMC4155520 | biostudies-literature
UnknownA 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Not available
S-EPMC4207729 | biostudies-literature
UnknownA Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.
Not available
S-EPMC7189949 | biostudies-literature
UnknownThe Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Not available
S-EPMC10566451 | biostudies-literature
UnknownFive-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial.
Not available
S-EPMC12712729 | biostudies-literature
Sort   by:  
 Page size